Skip to main content
Leiden University
Scholarly Publications
Home
Submit
About
Select Collection
All collections
Academic speeches
Dissertations
Faculty of Archaeology
Faculty of Governance and Global Affairs
Faculty of Humanities
Faculty of Science
Faculty of Social and Behavioural Sciences
Leiden Journals, Conference Proceedings and Books
Leiden Law School
Leiden University Press
Medicine / Leiden University Medical Centre (LUMC)
Research output UL
Search box
Your Search
Enabled Filters
(-)
= Leeuwen-Stok, A.E. van
Sort Options
Date (year)
Author / Creator
Title
Refine Results
Resource Type
Article / Letter to editor
(17)
+
-
Availability
Open access
(3)
+
-
Metadata Only
(14)
+
-
Creation Date
2014
(4)
+
-
2013
(3)
+
-
2015
(3)
+
-
2017
(2)
+
-
2018
(2)
+
-
Faculty
Leiden University Medical Center (LUMC)
(17)
+
-
Collection
Medicine / Leiden University Medical Centre (LUMC)
(17)
+
-
Topic
Breast cancer
(3)
+
-
Chemotherapy
(2)
+
-
Metastatic breast cancer
(2)
+
-
Author
Leeuwen-Stok, A.E. van
(17)
+
-
Nortier, J.W.R.
(13)
+
-
Kroep, J.R.
(11)
+
-
Velde, C.J.H. van de
(10)
+
-
Liefers, G.J.
(8)
+
-
Charehbili, A.
(7)
+
-
Maartense, E.
(7)
+
-
Putter, H.
(7)
+
-
Tinteren, H. van
(6)
+
-
Smit, V.T.H.B.M.
(5)
+
-
Bochove, A. van
(4)
+
-
Kranenbarg, E.M.K.
(4)
+
-
Kranenbarg, E.M.M.K.
(4)
+
-
Linn, S.C.
(4)
+
-
Portielje, J.E.A.
(4)
+
-
Wasser, M.N.
(4)
+
-
Blok, E.J.
(3)
+
-
Bosch, J. van den
(3)
+
-
Graaf, H. de
(3)
+
-
Groot, S.M. de
(3)
+
-
Hamaker, M.E.
(3)
+
-
Hoeven, J.J.M. van der
(3)
+
-
Kok, M.
(3)
+
-
Laarhoven, H.W.M. van
(3)
+
-
Mandjes, I.A.M.
(3)
+
-
Oosterkamp, H.M.
(3)
+
-
Rossum, A.G.J. van
(3)
+
-
Rutgers, E.J.T.
(3)
+
-
Seynaeve, C.
(3)
+
-
Smorenburg, C.H.
(3)
+
-
Werkhoven, E. van
(3)
+
-
Braun, J.J.
(2)
+
-
Dijkgraaf, E.M.
(2)
+
-
Dutch Breast Canc Res Grp BOOG
(2)
+
-
Groot, S. de
(2)
+
-
Hamdy, N.A.T.
(2)
+
-
Heijns, J.B.
(2)
+
-
Imholz, A.L.T.
(2)
+
-
Janssen, L.G.M.
(2)
+
-
Jongh, F.E. de
(2)
+
-
Kessels, L.
(2)
+
-
Kessels, L.W.
(2)
+
-
M. los
(2)
+
-
Opdam, M.
(2)
+
-
Pijl, H.
(2)
+
-
Rutgers, E.J.
(2)
+
-
Smit, V.T.
(2)
+
-
Ven, S. van de
(2)
+
-
Wesseling, J.
(2)
+
-
Show more
Language
en
(17)
+
-
Search results
(1 - 17 of 17)
show grid
show list
save search
Differential survival and therapy benefit of patients with breast cancer are characterized by distinct epithelial and immune cell microenvironments
Carboplatin-cyclophosphamide or paclitaxel without or with bevacizumab as first-line treatment for metastatic triple-negative breast cancer (BOOG 2013-01)
Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04)
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)
Safety assessment of extended adjuvant endocrine therapy with letrozole; results of the randomized phase III IDEAL trial (BOOG 2006-05)
Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006-05)
Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01)
Thyroid function is associated with the response to neoadjuvant chemotherapy in breast cancer patients: Results from the NEOZOTAC trial on behalf of the Dutch Breast Cancer Research Group (BOOG 2010-01)
Results from a randomized phase II study of the Dutch Breast Cancer Research Group (BOOG 2008-03): Concomitant trastuzumab, bevacizumab and paclitaxel (HAT) versus trastuzumab and bevacizumab, followed by trastuzumab, bevacizumab and paclitaxel (HA- HAT)
Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)
Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer
Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01)
A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG
Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: Results from the OMEGA study of the Dutch Breast Cancer Trialists' Group
Accuracy of treatment response assessment modalities after neoadjuvant therapy: A Dutch Breast Cancer Trialists' Group (BOOG) substudy
Clinical and pathological response after neoadjuvant chemotherapy with or without zoledronic acid for patients with HER2-negative large resectable or stage II or III breast cancer
Slow accrual of elderly patients with metastatic breast cancer in the Dutch multicentre OMEGA study
